Royal Philips’ IGT Goes For The Structural Heart
Value Based Concepts Also Apply In Diagnosis And Treatment
Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains.
You may also be interested in...
The plum in the middle of Philips' intense period of M&A this summer was the €1.9 billion purchase of Spectranetics, which, combined with Philips Volcano, should create a $1 billion+ devices business within the image-guided therapy group by 2020. IGT senior vice president and general manager Bert van Meurs explains the rationale behind the deal, and what's next for Philips.
All eyes were on the European Commission in January as it edged closer to adopting new legislation that will see the Medical Device Regulation transition deadlines extended.
One outcome of last year’s public consultation on UK MHRA fees is a hefty uplift in charges payable by medtech manufacturers in 2023, beyond which the agency is keen to pursue a new fees and charges plan.